UPSTREAM BIO INC (UPB) competitors & alternatives
Health Care · NASDAQ
UPSTREAM BIO INC (UPB)'s top competitors and alternatives — its most similar public companies — include Amgen (AMGN), CONNECT BIOPHARMA HOLDINGS LTD (CNTB), ZURA BIO LTD CLASS A (ZURA), CLIMB BIO INC (CLYM), TREVI THERAPEUTICS INC (TRVI), IMMUNOVANT INC (IMVT), ELEDON PHARMACEUTICALS INC (ELDN), REZOLUTE INC (RZLT), Aldeyra Therapeutics, Inc. (ALDX), BridgeBio Oncology Therapeutics, Inc. (BBOT), DESIGN THERAPEUTICS INC (DSGN) and MONOPAR THERAPEUTICS INC (MNPR). These are UPSTREAM BIO INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top UPB competitors & alternatives
-
AmgenAMGNHealth Care
A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone…
$366.05 (as of 2026-07-22) · market cap $197.7B
-
CONNECT BIOPHARMA HOLDINGS LTDCNTBHealth Care
Clinical-stage biopharmaceutical company developing rademikibart, an IL-4Rα-targeting monoclonal antibody to treat acute exacerbations of asthma and COPD.
$2.20 (as of 2026-07-22) · market cap $139M
-
ZURA BIO LTD CLASS AZURAHealth Care
Zura Bio is developing differentiated bispecific and monoclonal antibodies targeting immune pathways in autoimmune and inflammatory diseases where current…
$5.40 (as of 2026-07-22) · market cap $532M
-
CLIMB BIO INCCLYMHealth Care
Clinical-stage biotech developing budoprutug, an anti-CD19 monoclonal antibody for B-cell depletion in autoimmune diseases including membranous nephropathy and…
$12.58 (as of 2026-07-22) · market cap $720M
-
TREVI THERAPEUTICS INCTRVIHealth Care
Trevi Therapeutics is a clinical-stage biotech developing Haduvio, an oral, non-scheduled dual-action opioid receptor drug, to treat chronic cough associated…
$17.36 (as of 2026-07-22) · market cap $2.5B
-
IMMUNOVANT INCIMVTHealth Care
Immunovant is a clinical-stage immunology company developing IMVT-1402, a potentially best-in-class FcRn inhibitor to treat autoimmune diseases driven by…
$39.05 (as of 2026-07-22) · market cap $8.0B
-
ELEDON PHARMACEUTICALS INCELDNHealth Care
Eledon Pharmaceuticals is a clinical-stage biotech developing immune-modulating therapies for autoimmune diseases and organ transplantation.
$3.72 (as of 2026-07-22) · market cap $287M
-
REZOLUTE INCRZLTHealth Care
Rezolute is a clinical-stage biopharmaceutical company developing targeted therapeutic solutions for rare and chronic metabolic and endocrine diseases.
$5.00 (as of 2026-07-22) · market cap $481M
-
Aldeyra Therapeutics, Inc.ALDXHealth Care
Aldeyra is a clinical-stage biotech pursuing FDA approval of reproxalap, an aldehyde dehydrogenase activator for ophthalmologic inflammation, dependent on…
$1.70 (as of 2026-07-22) · market cap $106M
-
BridgeBio Oncology Therapeutics, Inc.BBOTHealth Care
BridgeBio Oncology is advancing next-generation small-molecule inhibitors of RAS and PI3K pathways for previously untreatable solid tumors including…
$8.90 (as of 2026-07-22) · market cap $701M
-
DESIGN THERAPEUTICS INCDSGNHealth Care
A clinical-stage biotechnology company pioneering a novel class of small-molecule GeneTAC therapeutics to treat serious genetic diseases by modulating gene…
$11.78 (as of 2026-07-22) · market cap $736M
-
MONOPAR THERAPEUTICS INCMNPRHealth Care
Monopar Therapeutics is a clinical-stage biopharmaceutical firm focused on developing innovative radiopharmaceuticals for cancer and specialized treatments for…
$112.48 (as of 2026-07-22) · market cap $752M
Not quite? Describe exactly what you want →
Peers are UPSTREAM BIO INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: UPSTREAM BIO INC (UPB).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.